Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0778
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2620
    -0.0003 (-0.02%)
     
  • USD/JPY

    151.4350
    +0.0630 (+0.04%)
     
  • Bitcoin USD

    70,161.53
    +393.70 (+0.56%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,463.25
    +295.18 (+0.73%)
     

Bristol-Myers Looks To A Promising Future

Pharmaceutical company Bristol-Myers Squibb Co (NYSE: BMY) has some big opportunities on the horizon, and analysts are taking notice.

At a time when many pharma companies are beginning to worry about political battles over lowering drug prices, Bristol-Myers Squibb is hoping its bright future will outweigh any negativity coming from Washington, as the company's cancer fighting drug Opdivo is set to become a major player in the cancer-treatment space throughout the coming years, according to Barron's.

Opdivo

Opdivo is an immuno-oncology drug that has been successful in blocking patients' T-cell receptors and helping their immune systems detect cancerous cells and attack them. Currently, Opdivo is the most successful immuno-oncology drug on the market and has been approved for use against three different types of cancer. Opdivo was also the subject of Bristol-Myers' latest ad campaign, as the firm looked to broaden patient interest in the drug.

Related Link: Barron's Picks And Pans: Bristol-Myers Squibb, KeyCorp, Core-Mark And More

Immuno-Oncology Shows Promise

Drugs that treat very specific illnesses or affect only a small segment of the population have become lucrative ways for drug companies to maintain their profits as more and more generic brands are created. At the moment, Bristol-Myers' Opdivo costs around $12,500 per month as there are no generic brands, making it a huge money maker for the company.

Pharma Sector Under Political Weight

With such a promising future ahead, many are questioning why shares of Bristol-Myers are down nearly 10 percent so far this year.

The pharmaceutical industry has declined on a whole this year, as the upcoming election has weighed on investor sentiment. Rising prescription drug prices have been a huge topic in this year's presidential campaigns, and many worry that the pharma sector will suffer once a new administration takes over.

Image Credit: Public Domain

See more from Benzinga

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement